Efficacy News and Research

RSS

Cornell researchers develop nanoparticle-based drug delivery mechanism for combination cancer therapy

A team of researchers from Cornell University in Ithaca, New York demonstrated a drug delivery mechanism that utilizes two independent vehicles, allowing for delivery of chemically and physically dis-tinct agents.

23 May 2016

Harvard researchers create new, simplified platform for antibiotic discovery

Harvard researchers have created a new, greatly simplified, platform for antibiotic discovery that may go a long way to solving the crisis of antibiotic resistance.

23 May 2016

DECT trial shows combination of epirubicin and trastuzumab improves outcomes in breast cancer patients

The study entitled "A phase II neoadjuvant sequential regimen of docetaxel followed by high-dose epirubicin in combination with cyclophosphamide administered concurrently with trastuzumab.

23 May 2016

Cochrane review explores FDCs versus single-drug formulations for treatment of pulmonary TB

A research team from Spain has prepared a Cochrane systematic review that explores the efficacy, safety, and adherence to fixed-dose combinations (FDCs) of drugs versus single-drug formulations to treat people who are newly diagnosed with tuberculosis (TB).

23 May 2016

Phase I study of triple drug combination shows promise in multiple myeloma patients

PharmaMar announces the positive results from a Phase I study of plitidepsin in combination with bortezomib and dexamethasone in patients with relapsed and/or refractory multiple myeloma.

21 May 2016

Malicious form of ATF2 protein drives formation of melanoma

An international collaborative study led by scientists at the Sanford Burnham Prebys Medical Discovery Institute has identified a malicious form of a protein that drives the formation of melanoma.

20 May 2016

Arthroscopic surgery may not be best option for older, arthritis patients

For patients with serious, ongoing hip pain, sometimes surgery is their best bet for relief. Given the choice between minimally invasive hip surgery and total hip replacement, most patients would choose the less invasive procedure, often done on an outpatient basis.

20 May 2016

UK's first heart operation uses new Topera system to analyse electrical activity during AF

The UK's first heart operations using a novel software platform to pinpoint the source of the heart condition have been carried out in Leicester thanks to research at the University of Leicester.

19 May 2016

New drug that combines methicillin with polymer BPEI can combat MRSA

A University of Oklahoma team of chemists has developed a new antibiotic formulation to fight the sometimes deadly staph infection caused by methicillin-resistant S. aureus or MRSA and other antibiotic-resistant infectious bacteria.

19 May 2016

Clinicians perform UK’s first MRI-guided focused ultrasound treatment for prostate cancer

INSIGHTEC congratulates the medical team at Imperial College Healthcare NHS Trust for performing the first MR-guided focused ultrasound treatment in the United Kingdom for prostate cancer.

19 May 2016

Early high-dose rhEPO fails to improve neurodevelopment in very preterm infants

Very preterm infants do not gain protection against neurodevelopmental delay with early prophylactic high-dose recombinant human erythropoietin, researchers report.

19 May 2016

Tecentriq drug gets FDA approval to treat urothelial carcinoma

The U.S. Food and Drug Administration today approved Tecentriq (atezolizumab) to treat the most common type of bladder cancer, called urothelial carcinoma. This is the first product in its class (PD-1/PD-L1 inhibitors) approved to treat this type of cancer.

19 May 2016

Tackling Zika: are insect repellents the answer? An interview with Bruno Jactel

The repellents that are used today are mostly based on what we call chemical pesticides. These products are used to repel mosquitoes as well as ticks. They are very broadly used, but there are different issues surrounding their use.

19 May 2016

Targeting rotors challenged for nonparoxsymal AF

Targeted ablation of electrical rotors and focal sources is not a successful strategy in patients with persistent or long-standing atrial fibrillation, shows the randomised OASIS trial.

18 May 2016

First-ever clinical trial of bioabsorbable cardiovascular device in children shows promise

Current cardiovascular valve or blood vessel implants are generally associated with a number of complications, have limited efficacy over time, and may necessitate repeated interventions over a patient's lifetime, especially when implanted in a young child.

18 May 2016

Biovica acquires cSens AB - creating opportunities for solving cancer diagnostic challenges

Biovica has acquired cSens AB, a company that has developed a PCR-based platform for the analysis of serum thymidine kinase (TK) enzyme activity, which correspond to tumor proliferation and cancer aggressiveness.

18 May 2016

PCI with polymer-free BA9 drug-coated stent better than bare metal stent in ACS patients

Patients with acute coronary syndromes (ACS) who are at high risk for bleeding have significantly lower rates of target lesion revascularisation and fewer adverse events after undergoing percutaneous coronary intervention (PCI) with a polymer-free biolimus-A (BA9) drug-coated stent than with those receiving a bare metal stent (BMS) in results from a sub-study of the LEADERS FREE trial reported for the first time in a late-breaker session at EuroPCR 2016.

17 May 2016

Novel therapeutic approach to treat leukaemia patients

Cancer cells have an abnormal cell division and survival machinery - they grow faster than they die. For their permanent development, they produce an excess of growth factors and nutrients and block the body's own safety mechanisms.

17 May 2016

FDA approves additional indication for Eisai's anticancer agent Lenvima in combo with Everolimus for advanced renal cell carcinoma

Eisai Co., Ltd. has announced that its U.S. subsidiary Eisai Inc. has received approval from the U.S. Food and Drug Administration (FDA) for an additional indication for Eisai's in-house developed novel anticancer agent Lenvima (lenvatinib mesylate) in combination with everolimus for the treatment of patients with advanced renal cell carcinoma following one prior anti-angiogenic therapy.

16 May 2016

GammaCore both effective and cost effective for the treatment of cluster headache

A paper in the Journal of Headache and Pain reports that non-invasive stimulation of the vagus nerve (nVNS) is a cost effective therapy for cluster headache. These findings were based on reductions in medication use and improvements in quality of life. The publication also notes that further economic benefits would have been found had reduced visits to clinics been taken into account.

16 May 2016

Efficacy News and Research

Cornell researchers develop nanoparticle-based drug delivery mechanism for combination cancer therapy

Harvard researchers create new, simplified platform for antibiotic discovery

DECT trial shows combination of epirubicin and trastuzumab improves outcomes in breast cancer patients

Cochrane review explores FDCs versus single-drug formulations for treatment of pulmonary TB

Phase I study of triple drug combination shows promise in multiple myeloma patients

Malicious form of ATF2 protein drives formation of melanoma

Arthroscopic surgery may not be best option for older, arthritis patients

UK's first heart operation uses new Topera system to analyse electrical activity during AF

New drug that combines methicillin with polymer BPEI can combat MRSA

Clinicians perform UK’s first MRI-guided focused ultrasound treatment for prostate cancer

Early high-dose rhEPO fails to improve neurodevelopment in very preterm infants

Tecentriq drug gets FDA approval to treat urothelial carcinoma

Tackling Zika: are insect repellents the answer? An interview with Bruno Jactel

Targeting rotors challenged for nonparoxsymal AF

First-ever clinical trial of bioabsorbable cardiovascular device in children shows promise

Biovica acquires cSens AB - creating opportunities for solving cancer diagnostic challenges

PCI with polymer-free BA9 drug-coated stent better than bare metal stent in ACS patients

Novel therapeutic approach to treat leukaemia patients

FDA approves additional indication for Eisai's anticancer agent Lenvima in combo with Everolimus for advanced renal cell carcinoma

GammaCore both effective and cost effective for the treatment of cluster headache

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News